TAF Placebo

DRUG5 trials

Sponsors

Gilead Sciences

Conditions

Chronic HBV InfectionChronic Hepatitis BHBVHBeAg-negative Chronic Hepatitis BHBeAg-positive Chronic Hepatitis B

Phase 3

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

CompletedNCT01940471

Gilead SciencesHBeAg-positive Chronic Hepatitis B

Start: 2013-09-11End: 2022-10-13Updated: 2023-10-10

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

CompletedNCT01940341

Gilead SciencesHBeAg-negative Chronic Hepatitis B

Start: 2013-09-12End: 2022-08-31Updated: 2023-09-25

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

CompletedNCT02836236

Gilead SciencesChronic HBV Infection, HBV

Start: 2015-06-19End: 2023-09-18Updated: 2024-10-02

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

CompletedNCT02836249

Gilead SciencesChronic HBV Infection, HBV

Start: 2015-06-19End: 2023-08-31Updated: 2024-10-15

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

CompletedNCT02979613

Gilead SciencesChronic Hepatitis B

Start: 2016-12-29End: 2020-01-30Updated: 2020-09-14

Related Papers

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Alimentary Pharmacology & Therapeutics2024-09-2719 citations

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

JHEP Reports2023-07-1319 citations

3-year Treatment of Tenofovir Alafenamide <i>vs</i>. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China.

2021-04-2825 citations

S1070 A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results

The American Journal of Gastroenterology2020-10-011 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.

2020-02-2093 citations

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.

2018-09-2437 citations

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

2018-06-2024 citations

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

2018-01-17284 citations

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

2016-09-22341 citations

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

2016-09-22328 citations